The term sarcopenia, derived from the Greek words sarx for flesh and penia for loss, was first
introduced by Rosenberg 1 in 1989 to describe the loss of muscle mass that accompanies …

Background The evidence that body composition parameters influence multiple cancer
outcomes is rapidly expanding. Excess adiposity deposits in muscle tissue, termed …

Body composition, defined as the proportions and distribution of lean and fat tissues in the
human body, is an emergent theme in clinical oncology. Severe muscle depletion …

Clinicians often believe that cachexia is caused by cancer and anorexia as a toxicity of
chemotherapy or targeted anti-cancer agents. It is now recognized that chemotherapy and …

Objectives Low skeletal muscle mass (SMM) or sarcopenia is emerging as an adverse
prognostic factor for chemotherapy dose-limiting toxicity (CLDT) and survival in cancer …

The aim of this study was to investigate the clinical impact of sarcopenia on the efficacy of
programmed death (PD)-1 inhibitors. We retrospectively reviewed the medical records of all …

Rationale and Objectives To assess whether a fully-automated deep learning system can
accurately detect and analyze truncal musculature at multiple lumbar vertebral levels and …

Cancer cachexia is a complex multi‐organ catabolic syndrome that reduces mobility,
increases fatigue, decreases the efficiency of therapeutic strategies, diminishes the quality of …

Background The purpose of the present meta‐analysis was to analyze the prevalence of
sarcopenia on staging computed tomography (CT) in patients with different malignant solid …

Background Low muscle mass (LMM) and low muscle attenuation (LMA) reflect low muscle
quantity and low muscle quality, respectively. Both are associated with a poor outcome in …